Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as ...

Shares of Gilead Sciences Inc. rose 4.21% to $122.81 Friday, on what proved to be an all-around great trading session for the ...

Shares of a major credit card issuer surged on Friday, Oct. 17, 2025, as spending by wealthy cardholders helped drive record ...

BERLIN -- For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall ...

Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek ...

The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...

Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.

Gilead Sciences (GILD) is drawing attention this week as it presents new clinical results at both the European AIDS ...

In the first opportunity for industry watchers to compare the two approved TROP2 antibody-drug conjugates side by side in ...

AstraZeneca and Gilead both reported successful trials in a hard-to-treat form of breast cancer, sparking a debate about ...

Gilead Sciences Inc. (GILD) reached a notable milestone as its stock hit a 52-week high of $121.84, with InvestingPro data ...

AstraZeneca and Daiichi Sankyo’s Datroway boosts survival in triple-negative breast cancer, showing strong results at ESMO ...